We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus
Read MoreHide Full Article
Clinical-stage company, Prothena Corporation (PRTA - Free Report) reported earnings of $2.13 per share, missing the Zacks Consensus Estimate of $2.25. In the year-ago quarter, the company reported a loss of 77 cents.
Total revenues came in at $139.2 million in the quarter, missing the Zacks Consensus Estimate of $140 million. Revenues in the third quarter included collaboration revenues of $78.5 million from Bristol Meyer Squibb (BMY - Free Report) for the option exercise and U.S. license for PRX005 and intellectual property revenues of $60.7 million from the sale of the intellectual property and related rights to its ATTR amyloidosis business and pipeline to Novo Nordisk (NVO - Free Report) . In the year-ago quarter, the company earned revenues of $157,000.
The company’s shares have surged 369.9% in the year so far against the industry’s decline of 6.8%.
Image Source: Zacks Investment Research
Quarter in Detail
R&D expenses were $18 million, down from $21.6 million in the year-ago quarter, primarily due to lower manufacturing costs primarily related to PRX005 and birtamimab programs.
General and administrative (G&A) expenses were $11.9 million, up from $9.4 million in the year-ago quarter, primarily due to higher personnel and legal expenses and increased expenses for the directors’ and officers’ insurance premium.
As of Sep 30, 2021, Prothena had $601.5 million in cash, cash equivalents and restricted cash, and no debt.
Pipeline Updates
The company is evaluating prasinezumab in collaboration with Roche (RHHBY - Free Report) for the treatment of Parkinson’s disease.
It is also evaluating birtamimab, a potential treatment for AL amyloidosis. A confirmatory phase III AFFIRM-AL study of birtamimab in Mayo Stage IV patients with AL amyloidosis is ongoing.
Novo Nordisk has acquired its clinical-stage antibody, PRX004, and broader ATTR amyloidosis program. Prothena is eligible to receive a total aggregate of up to $1.23 billion and has received $60 million upfront payment from the former to date.
Meanwhile, it is advancing an early-stage pipeline of programs for a number of potential neurological indications with Bristol Meyer. PRX005 — a potential treatment for Alzheimer’s disease (AD) — is an investigational antibody that targets tau, a protein implicated in diseases including AD, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies. The company has received $80 million option payment from Bristol Myers for the execution of U.S. license agreement.
Prothena is also evaluating PRX012, an investigational high-potency monoclonal antibody targeting a key epitope at the N-terminus of amyloid beta (Aβ) for the treatment of AD. An investigational new drug application (IND) is expected in the first quarter of 2022.
The company is also developing a dual Aβ-Tau vaccine — a potential prevention and treatment for AD — to target key epitopes within Aβ and tau proteins for promoting amyloid clearance as well as blockade pathogenic tau interaction. An IND for the vaccine is anticipated in 2023.
Prothena Corporation plc Price, Consensus and EPS Surprise
Image: Bigstock
Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus
Clinical-stage company, Prothena Corporation (PRTA - Free Report) reported earnings of $2.13 per share, missing the Zacks Consensus Estimate of $2.25. In the year-ago quarter, the company reported a loss of 77 cents.
Total revenues came in at $139.2 million in the quarter, missing the Zacks Consensus Estimate of $140 million. Revenues in the third quarter included collaboration revenues of $78.5 million from Bristol Meyer Squibb (BMY - Free Report) for the option exercise and U.S. license for PRX005 and intellectual property revenues of $60.7 million from the sale of the intellectual property and related rights to its ATTR amyloidosis business and pipeline to Novo Nordisk (NVO - Free Report) . In the year-ago quarter, the company earned revenues of $157,000.
The company’s shares have surged 369.9% in the year so far against the industry’s decline of 6.8%.
Quarter in Detail
R&D expenses were $18 million, down from $21.6 million in the year-ago quarter, primarily due to lower manufacturing costs primarily related to PRX005 and birtamimab programs.
General and administrative (G&A) expenses were $11.9 million, up from $9.4 million in the year-ago quarter, primarily due to higher personnel and legal expenses and increased expenses for the directors’ and officers’ insurance premium.
As of Sep 30, 2021, Prothena had $601.5 million in cash, cash equivalents and restricted cash, and no debt.
Pipeline Updates
The company is evaluating prasinezumab in collaboration with Roche (RHHBY - Free Report) for the treatment of Parkinson’s disease.
It is also evaluating birtamimab, a potential treatment for AL amyloidosis. A confirmatory phase III AFFIRM-AL study of birtamimab in Mayo Stage IV patients with AL amyloidosis is ongoing.
Novo Nordisk has acquired its clinical-stage antibody, PRX004, and broader ATTR amyloidosis program. Prothena is eligible to receive a total aggregate of up to $1.23 billion and has received $60 million upfront payment from the former to date.
Meanwhile, it is advancing an early-stage pipeline of programs for a number of potential neurological indications with Bristol Meyer. PRX005 — a potential treatment for Alzheimer’s disease (AD) — is an investigational antibody that targets tau, a protein implicated in diseases including AD, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies. The company has received $80 million option payment from Bristol Myers for the execution of U.S. license agreement.
Prothena is also evaluating PRX012, an investigational high-potency monoclonal antibody targeting a key epitope at the N-terminus of amyloid beta (Aβ) for the treatment of AD. An investigational new drug application (IND) is expected in the first quarter of 2022.
The company is also developing a dual Aβ-Tau vaccine — a potential prevention and treatment for AD — to target key epitopes within Aβ and tau proteins for promoting amyloid clearance as well as blockade pathogenic tau interaction. An IND for the vaccine is anticipated in 2023.
Prothena Corporation plc Price, Consensus and EPS Surprise
Prothena Corporation plc price-consensus-eps-surprise-chart | Prothena Corporation plc Quote
Our Take
While the company missed on earnings and revenues in the third quarter, the progress with its AD candidates is impressive and promises potential.
Prothena currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.